Sarepta therapeutics reports preliminary* fourth quarter and full-year 2023 net product revenue

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2023 net product revenue and cash on hand as of december 31, 2023, as part of its presentation today at the 42nd annual j.p. morgan healthcare conference in san francisco, calif. financial update* (preliminary and unaudited): fourth quarter and full-year 2023 net product revenue for elevidys are expected.
SRPT Ratings Summary
SRPT Quant Ranking